Search for: "Astrazeneca LP"
Results 1 - 20
of 155
Sort by Relevance
|
Sort by Date
18 Mar 2024, 9:46 am
AstraZeneca Pharmaceuticals, LP 23-665Issue: Whether, where an unemployment applicant’s religious beliefs are independently sufficient to cause her refusal to follow an employer policy, a state can deny her unemployment benefits by holding that philosophical and personal beliefs outweigh her religious beliefs. [read post]
12 Mar 2024, 12:46 pm
Astrazeneca Pharms., LP, 500 F. [read post]
19 Oct 2023, 4:00 am
AstraZeneca Pharmaceuticals LP, (D MD, Oct. 17, 2023), a Maryland federal district court dismissed a Title VII religious discrimination claim by two employees who were denied a religious exemption from a company's Covid vaccine mandate, finding that their objections were not religious in nature. [read post]
4 Jan 2022, 6:00 am
Cir. 2021) 2021-1729 AstraZeneca AB and AstracZeneca Pharmacueticals LP (AstraZeneca) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. [read post]
9 Dec 2021, 7:15 am
The decision relates to AstraZeneca AB’s and AstraZeneca Pharmaceuticals LP’s (collectively “AstraZeneca”) lawsuit against Mylan and Kindeva Drug Delivery LP (collectively “Mylan”) for infringing all claims of U.S. [read post]
8 Dec 2021, 8:52 am
The outcome AstraZeneca AB and AstraZeneca Pharmaceuticals LP (collectively, “AstraZeneca”) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. [read post]
5 Aug 2021, 12:12 pm
The outcome was a vacating of the district court's grant of JMOL and a lot of discussion of drug "skinny labels": GlaxoSmithKline LLC and SmithKline Beecham (Cork) Ltd. [read post]
17 Aug 2020, 10:03 am
AstraZeneca Pharmaceuticals LP, Civil Action No. 19-2320-RGA (D.Del. [read post]
13 May 2020, 2:03 am
Astrazeneca Pharms., LP, 500 F. [read post]
12 Feb 2018, 12:05 pm
According to that JPML Transfer Order the Defendants -- AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co., and McKesson Corp. -- opposed centralization of approximately 80 Onglyza and Kombiglyze lawsuits into this new MDL: Defendants oppose transfer by arguing that plaintiffs’ allegations are supported by a single study (the SAVOR study), which itself supports only claims regarding heart failure – not the various other injuries (congestive heart failure, acute… [read post]
11 Nov 2017, 11:00 am
See AstraZeneca LP v. [read post]
10 Oct 2017, 4:12 pm
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
10 Oct 2017, 4:12 pm
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
12 May 2017, 9:05 am
., AstraZeneca Pharmaceuticals LP, AstraZeneca LP, AstraZeneca PLC, and AstraZeneca AB (collectively, Bristol-Myers/AstraZeneca), which developed, manufactured, and marketed the drugs, failed to adequately test the drugs and warn of their risks. [read post]
6 May 2017, 10:11 am
The decision Braintree v. [read post]
4 May 2017, 6:55 am
Astrazeneca Pharmaceutical, LP, May 2, 2017, Thompson, O.). [read post]
28 Feb 2017, 7:39 am
The particular claims require “a continuous long term regimen . . . at a dosage up to 1.5 mg/kg/day for not less than 45 days” for treating “an individual with … penile tunical fibrosis …” On anticipation, the court drew a fine-line with its closest case being AstraZeneca LP v. [read post]
8 Dec 2016, 2:00 am
Linda O'BrienCCHPurchasers of AstraZeneca LP’s heartburn medication Nexium were not entitled to a new trial to their challenge of “reverse payment” agreements between AstraZeneca and Ranbaxy Pharmaceuticals that allegedly blocked the entry of a generic version of the drug, the U.S. [read post]
29 Aug 2016, 12:30 pm
For use as an example, here is the relevant part of an August 17, 2016 FDA Supplemental Approval letter to AstraZeneca Pharmaceuticals LP for Farxiga: Please refer to your supplemental New Drug Application (sNDA) dated and received July 28 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Farxiga (dapagliflozin) tablets. [read post]
23 May 2016, 7:49 am
The Court reasoned that (1) like the generic in AstraZeneca Pharmaceuticals LP v. [read post]
